ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I

Description

A first-in-human study using ISP-001 in adult patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.

Conditions

Mucopolysaccharidosis IH/S, Mucopolysaccharidosis IS

Study Overview

Study Details

Study overview

A first-in-human study using ISP-001 in adult patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.

A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Adult Patients With Mucopolysaccharidosis Type I Hurler-Scheie and Scheie

ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I

Condition
Mucopolysaccharidosis IH/S
Intervention / Treatment

-

Contacts and Locations

Minneapolis

University of Minnesota, Minneapolis, Minnesota, United States, 55455

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of Mucopolysaccharidosis type I Hurler-Scheie or Scheie syndrome.
  • * Age ≥ 18 years at time of study registration.
  • * Creatinine clearance, calculated or measured directly, that is \>60ml/min/1.73m2.
  • * Ejection fraction ≥ 40% by echocardiogram.
  • * Must commit to traveling to the study site for the necessary follow-up evaluations.
  • * Must agree to stay \<45-minute drive from the study site for a minimum of 5 days after cell infusion.
  • * Known familial inherited cancer syndrome. Suspected cases will be investigated, per the physicians discretion, using relevant genetic tests to determine presence of germline mutations.
  • * History of B cell related cancer, EBV lymphoproliferative disease or autoimmune disorders.
  • * Evidence of active graft-vs-host disease.
  • * Underwent a previous hematopoietic stem cell transplant (HSCT).
  • * Requirement for systemic immune suppression.
  • * Requirement for continuous supplemental oxygen.
  • * Any medical condition likely to interfere with assessment of safety or efficacy of the study treatment.
  • * In the investigator's judgement, the subject is unlikely to complete all protocol-required study visits or procedures, including follow up visits, or comply with the study requirements for participation.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Immusoft of CA, Inc.,

Immusoft Clinical Development, STUDY_DIRECTOR, Immusoft of CA, Inc.

Study Record Dates

2039-06-01